CINCINNATI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal fourth quarter and full year 2024 financial results on Monday, December 16, 2024, after market close. Gregory Crawford, Chief Executive Officer, and Hardik Mehta, Chief Financial Officer, will host a conference call for the investment community on Tuesday, December 17, 2024, at 10:00 a.m. (ET).
The call-in numbers for participants are:
Canada/US Toll Free: 1 (844) 763 8274
International: 1 (647) 484 8814
A live webcast of the call will be accessible via the investor section of the Company’s website through the following link: www.quipthomemedical.com.
ABOUT QUIPT HOME MEDICAL
The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.
For further information please visit our website at www.quipthomemedical.com, or contact:
Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
859-300-6455
This email address is being protected from spambots. You need JavaScript enabled to view it.
Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
859-300-6455
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.49 |
| Daily Change: | 0.08 3.32 |
| Daily Volume: | 489,959 |
| Market Cap: | US$107.290M |
December 18, 2023 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
